[O12] Oral Session 12　Rare Cancer / Cancer of Unknown Primary
【E】

[O12-1] Ramucirumab-containing chemotherapy for gastrointestinal neuroendocrine carcinoma: RAM-NEC study (WJOG13420G)

^○Yuki Matsubara¹, Toshiki Masuishi¹, Hidekazu Hirano², Saori Mishima³, Mitsuhiro Furuta⁴, Tomoyuki Otsuka⁵, Kenta Kawasaki⁶, Takeshi Kawakami⁷, Kazuhiro Yanagihara⁸, Takaya Shimura⁹, Masato Komoda¹⁰, Kozue Murayama¹¹, Keiko Minashi¹², Yoshiyuki Yamamoto¹³, Yudai Shinohara¹⁴, Shinichi Nishina¹⁵, Nobuyuki Musha¹⁶, Kyoko Kato¹⁷, Isao Oze¹⁸, Kei Muro¹ (1.Department of Clinical Oncology, Aichi Cancer Center Hospital, 2.Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 3.Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 4.Division of Gastroenterology, Kanagawa Cancer Center, 5.Department of Medical Oncology, Osaka International Cancer Institute, 6.Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 7.Gastrointestinal Oncology, Shizuoka Cancer Center Hospital, 8.Department of Medical Oncology, Kansai Electric Power Hospital, 9.Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 10.Department of Gastrointestinal and Medical Oncology, National Kyushu Cancer Center, 11.Department of Gastroenterology, Saitama Cancer Center, 12.Clinical Trial Promotion Department, Chiba Cancer Center, 13.Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, 14.Department of Hematology/Oncology, Japan Community Healthcare Organization Kyushu Hospital, 15.Department of Medical Oncology, Kurashiki Central Hospital, 16.Department of Surgery, Saiseikai Niigata Hospital, 17.Department of Medical Oncology, National Hospital Organization Nagoya Medical Center, 18.Division of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute)